Pomalidomide

• Background:

  Pomalidomide, a derivative of thalidomide, is an inhibitor TNF-α production (1), enhances the activity of T cells and natural killer cells and enhances antibody- dependent cellular cytotoxicity. It also may inhibit tumor angiogenesis, and promote cell cycle arrest (2).

• Description:

  E3 Ubiquitin Ligase Inhibitor

• Product Name Alternative:

  1,3-Dioxo-2- (2,6-dioxopiperidin-3-yl) -4-aminoisoindoline; 3-amino-N- (2,6-dioxo-3-piperidyl) phthalamide

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cancer | Cancer Growth Inhibitors | Angiogenesis Inhibitors | Cell Signaling | Post-translational Modifications | Ubiquitination | E3 Ubiquitin Ligases

• Purity:

  >98% (TLC) ; NMR (Conforms)

• Weight:

  0.005

• Format:

  Yellow powder

• Solubility:

  May be dissolved in DMSO (50 mg/ml)

• Molecular Formula:

  C13H11N3O4

• Molecular Weight:

  273.2

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. D'Amato R., Lentzsch S, Anderson K.C. ad Rogers M.S. (2001) Seminars in Oncology. 28(6): 597-601. 2. Fujiwara Y., et al. (2018) Cancer Research. DOI: 10.1158/0008-5472.CAN-18-1781

• CAS Number:

  19171-19-8